Perceptive Advisors LLC Buys New Position in Paratek Pharmaceuticals Inc (NASDAQ:PRTK)

Perceptive Advisors LLC bought a new stake in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 21,186 shares of the specialty pharmaceutical company’s stock, valued at approximately $532,000. Perceptive Advisors LLC owned approximately 0.08% of Paratek Pharmaceuticals as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of PRTK. Legal & General Group Plc grew its position in Paratek Pharmaceuticals by 13.3% in the 2nd quarter. Legal & General Group Plc now owns 5,865 shares of the specialty pharmaceutical company’s stock worth $144,000 after purchasing an additional 687 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Paratek Pharmaceuticals by 9.7% in the second quarter. Wells Fargo & Company MN now owns 17,075 shares of the specialty pharmaceutical company’s stock valued at $411,000 after acquiring an additional 1,509 shares in the last quarter. ProShare Advisors LLC boosted its holdings in shares of Paratek Pharmaceuticals by 14.1% in the second quarter. ProShare Advisors LLC now owns 16,191 shares of the specialty pharmaceutical company’s stock valued at $390,000 after acquiring an additional 2,005 shares in the last quarter. Nationwide Fund Advisors boosted its holdings in shares of Paratek Pharmaceuticals by 22.9% in the second quarter. Nationwide Fund Advisors now owns 13,355 shares of the specialty pharmaceutical company’s stock valued at $322,000 after acquiring an additional 2,492 shares in the last quarter. Finally, Alps Advisors Inc. boosted its holdings in shares of Paratek Pharmaceuticals by 10.2% in the third quarter. Alps Advisors Inc. now owns 27,339 shares of the specialty pharmaceutical company’s stock valued at $686,000 after acquiring an additional 2,530 shares in the last quarter. Institutional investors and hedge funds own 84.30% of the company’s stock.

PRTK has been the subject of a number of research reports. BidaskClub cut shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, December 2nd. Guggenheim started coverage on shares of Paratek Pharmaceuticals in a research report on Tuesday, October 24th. They issued a “buy” rating and a $44.00 price target for the company. Cantor Fitzgerald set a $50.00 price target on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, October 17th. Zacks Investment Research downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Finally, ValuEngine downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 18th. Two analysts have rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $40.00.

Paratek Pharmaceuticals Inc (NASDAQ PRTK) traded up $0.85 during midday trading on Tuesday, reaching $18.75. 345,389 shares of the company’s stock traded hands, compared to its average volume of 360,192. The company has a quick ratio of 10.53, a current ratio of 10.53 and a debt-to-equity ratio of 0.49. The firm has a market cap of $523.89, a price-to-earnings ratio of -5.03 and a beta of 0.71. Paratek Pharmaceuticals Inc has a 52 week low of $13.95 and a 52 week high of $29.00.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.truebluetribune.com/2018/01/03/perceptive-advisors-llc-takes-532000-position-in-paratek-pharmaceuticals-inc-prtk.html.

Paratek Pharmaceuticals Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply